Illumina Cambridge Limited

Illumina Cambridge Limited has been granted 253 US utility patents between 2015 and 2025, placing Illumina Cambridge Limited at rank #1,629 across all assignees tracked by PlainPatent. This portfolio spans 42 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.3 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Illumina Cambridge Limited is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 62.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 161 grants, compared with 92 in the 2015–2019 window — a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Illumina Cambridge Limited's 19.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 42 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Illumina Cambridge Limited against peers pursuing similar technology classes.